Ceapro Inc. (TSX-V: CZO;
OTCQX: CRPOF) (“Ceapro” or the
“Company”), a growth-stage biotechnology company focused
on the development and commercialization of active ingredients for
healthcare and cosmetic industries, today announced encouraging
results from it’s completed pre-clinical CHRP study conducted with
McMaster University evaluating PGX-processed yeast beta glucan
(PGX-YBG) as a potential therapeutic option for individuals
suffering from interstitial lung diseases (ILD).
The data were presented by Mrs. Safaa Naiel,
Ph.D. candidate, in an oral presentation titled, “Reprogramming
Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage
Modulator for Lung Fibrosis,” at the American Thoracic Society
(ATS) International Conference being held May 19-24, 2023 in
Washington, DC. The positive results from the CHRP study,
demonstrated PGX-YBG was respirable, and small enough to safely and
reliably reprogram macrophages in the lungs of mice, providing
confidence in its potential to safely penetrate deep into human
lungs when self-administered using a hand-held inhaler.
“We are excited about our progress on
formulating PGX-processed yeast beta glucans into inhalable dosage
forms as confirmed by industry-standard aerosolization testing
strategies, enhancing the translational potential of the technology
platform for human clinical use,” said Dr. Todd Hoare, Professor in
the Department of Chemical Engineering at McMaster University and
Canada Research Chair in Engineered Smart Materials and Principal
Investigator for this CHRP project.
ILD damages the tissues between the small air
sacs in the lungs (alveoli) and the blood vessels around them. This
makes it increasingly difficult to breathe, and progressively
harder for the oxygen to move out of the lungs and into the blood
and tissues where it is needed. ILD represent a significant unmet
medical need and is currently putting a major strain on healthcare
systems around the globe. In 2022, a peer-reviewed article
published in the journal of BMC Pulmonary Medicine reported that,
“globally, the median total direct cost for ILD equates to 51% of a
country’s GDP per capita and has been increasing over time.”1
One of the most prevalent and lethal ILD is
Idiopathic Pulmonary Fibrosis (IPF), an area of significant unmet
need. Prior to the pandemic, Ceapro and accomplished researchers
from McMaster University teamed up to develop a novel drug
formulation for the potential treatment of IPF. For the study,
researchers utilized yeast beta glucan (YBG), a fibre found in the
cell walls of baker’s yeast cells, which is known to stimulate the
body’s immune system to react to threats and which is used globally
as an immune stimulating natural health supplement. Conventional
spray dried YBG is not respirable as it is too large to enter the
human lung. In contrast, YBG that is processed using Ceapro’s
patented PGX technology (PGX-YBG) is highly purified, with a much
smaller particle size. Since PGX-YBG can be uniformly “loaded” with
a variety of bioactives, it was originally being investigated as a
delivery system for inhaled therapeutics. Through the research
collaboration, McMaster researchers found that, not only was
PGX-YBG a safe and effective carrier that could deliver therapeutic
actives, but that it also possesses the ability to reprogram the
body’s immune system to prevent fibrogenesis (the development of
harmful, fibrotic tissue) on its own. This encouraging result makes
PGX-YBG a promising novel active with high potential as a new
inhalable immune-therapeutic/-prophylactic treatment for a variety
of severe ILD including IPF and COVID-19 related lung fibrosis.
“Until now, we have had very limited treatment
options for fibrotic lung disease since approved medications can
only slow down the progression of the disease. We are very
encouraged by the results from this study showing that PGX-YBG has
the ability of reprogramming macrophages to prevent fibrogenesis in
mice. If these results are replicated in human trials, this
treatment approach could profoundly change the landscape of
fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a
respected Pulmonologist and Professor of Medicine at McMaster
University.
“Our initial hypothesis was that PGX-YBG
particles could be safely delivered into human lungs. These results
provide encouraging confirmation of that hypothesis and bolster our
confidence for the continued development toward a potential
treatment option for IPF,” stated Gilles Gagnon, President and CEO
of Ceapro. “This evidence, along with the latest in-vitro and
in-vivo data, provides the validation that PGX-YBG holds
significant potential as a therapeutic strategy for a broad
spectrum of fibrotic end-point lung diseases such as COVID-19
related lung fibrosis and IPF. With these results now in hand, we
are evaluating our pre-planned go/no-go decision for advancement of
this program into a Phase 1 clinical trial and expect to provide
updates in Q3 of this year.”
Additional results from these breakthrough
findings will be presented at other major conferences, including
results on aerosolization testing to be presented by Ph.D.
candidate, Nate Dowdall at The 2023 CSPS/CC-CRS Annual Symposium -
The Next Frontiers in Pharmaceutical Sciences to be held on May
24-26, 2023 at the Metropolitan Toronto Convention Centre (MTCC),
in an abstract titled, “Inhalable Yeast Beta-Glucan Microparticles
Prepared by Pressurized Gas eXpanded (PGX) Liquid Technology for
the Treatment of Fibrotic Lung Diseases.”About Idiopathic
Pulmonary Fibrosis (IPF)IPF is a progressive disease with
a median survival from 2-7 years. While IPF can occur at any age,
up to 1 out of every 200 individuals above age 65 have IPF. With an
aging population and studies showing an alarming rate (44.9%) of
COVID-19 patients developing IPF post infection2, prevalence and
impact of IPF are expected to grow.
About Pressurized Gas eXpanded Liquid Technology
(PGX)
Ceapro’s patented Pressurized Gas eXpanded (PGX)
Technology is a unique and disruptive technology with several key
advantages over conventional drying and purification technologies
that can be used to process biopolymers into high-value,
fine-structured, open-porous polymer structures and novel
biocomposites. PGX Technology is ideally suited for processing
challenging high-molecular-weight, water-soluble biopolymers. It
has the ability to make ultra-light, highly porous polymer
structures on a continuous basis, which is not possible using
today's conventional technologies. PGX Technology was invented by
Dr. Feral Temelli from the Department of Agricultural, Food &
Nutritional Science of the University of Alberta (U of A) along
with Dr. Bernhard Seifried, now Senior Director of Research and
Technology at Ceapro. The license from U of A provides Ceapro with
exclusive worldwide rights in all industrial
applications. About McMaster University
McMaster University, one of four Canadian
universities listed among the Top 100 universities in the world, is
renowned for its innovation in both learning and discovery. It has
a student population of 23,000 and more than 175,000 alumni in 140
countries. McMaster University is a globally renowned institution
of higher learning and an innovative research community committed
to advancing human and societal health and well-being. Our focus on
collaboratively exchanging ideas and approaches makes us uniquely
positioned to pioneer ground-breaking solutions to real-world
problems leading to a Brighter World.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company
involved in the development of proprietary extraction technology
and the application of this technology to the production of
extracts and “active ingredients” from oats and other renewable
plant resources. Ceapro adds further value to its extracts by
supporting their use in cosmeceutical, nutraceutical, and
therapeutics products for humans and animals. The Company has a
broad range of expertise in natural product chemistry,
microbiology, biochemistry, immunology and process engineering.
These skills merge in the fields of active ingredients,
biopharmaceuticals and drug-delivery solutions. For more
information on Ceapro, please visit the Company’s website at
www.ceapro.com.
For more information contact:
Jenene Thomas JTC Team, LLC Investor Relations and
Corporate Communications Advisor T (US): +1 (833)
475-8247 E: czo@jtcir.com
Issuer:Gilles R. Gagnon, M.Sc., MBAPresident & CEOT:
780-421-4555
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020025/
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983072/
Ceapro (TSXV:CZO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Ceapro (TSXV:CZO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024